Intech Investment Management LLC Acquires 2,971 Shares of Protagonist Therapeutics, Inc. $PTGX

Intech Investment Management LLC lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 9.6% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 33,953 shares of the company’s stock after acquiring an additional 2,971 shares during the quarter. Intech Investment Management LLC owned 0.05% of Protagonist Therapeutics worth $1,877,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new position in shares of Protagonist Therapeutics during the 2nd quarter valued at $27,000. Bessemer Group Inc. boosted its position in Protagonist Therapeutics by 171.0% during the second quarter. Bessemer Group Inc. now owns 504 shares of the company’s stock valued at $28,000 after buying an additional 318 shares during the period. CWM LLC boosted its position in Protagonist Therapeutics by 201.5% during the second quarter. CWM LLC now owns 609 shares of the company’s stock valued at $34,000 after buying an additional 407 shares during the period. Smartleaf Asset Management LLC grew its stake in shares of Protagonist Therapeutics by 141.7% during the first quarter. Smartleaf Asset Management LLC now owns 1,211 shares of the company’s stock valued at $59,000 after buying an additional 710 shares during the last quarter. Finally, Brooklyn Investment Group purchased a new position in shares of Protagonist Therapeutics in the first quarter worth about $68,000. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Performance

PTGX opened at $85.40 on Friday. The stock has a market capitalization of $5.34 billion, a PE ratio of 137.74 and a beta of 2.22. The stock’s 50 day moving average price is $73.71 and its 200-day moving average price is $60.21. Protagonist Therapeutics, Inc. has a 52-week low of $33.70 and a 52-week high of $93.25.

Protagonist Therapeutics (NASDAQ:PTGX) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.03). The business had revenue of $4.71 million during the quarter, compared to analysts’ expectations of $5.41 million. Protagonist Therapeutics had a return on equity of 6.86% and a net margin of 21.94%. Research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In other news, Director William D. Waddill sold 12,000 shares of Protagonist Therapeutics stock in a transaction dated Friday, October 10th. The shares were sold at an average price of $81.62, for a total transaction of $979,440.00. Following the sale, the director owned 5,130 shares of the company’s stock, valued at approximately $418,710.60. The trade was a 70.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last three months, insiders have sold 20,000 shares of company stock valued at $1,473,440. Company insiders own 4.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on PTGX shares. Wedbush increased their target price on Protagonist Therapeutics from $70.00 to $86.00 and gave the company an “outperform” rating in a report on Tuesday, October 28th. JMP Securities boosted their price objective on Protagonist Therapeutics from $67.00 to $69.00 and gave the company a “market outperform” rating in a research report on Thursday, August 7th. Citizens Jmp raised their target price on shares of Protagonist Therapeutics from $69.00 to $102.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. BTIG Research reaffirmed a “buy” rating and issued a $82.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday, October 28th. Finally, Citigroup upped their price target on shares of Protagonist Therapeutics from $96.00 to $98.00 and gave the company a “buy” rating in a report on Monday, November 10th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.23.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.